文献速递中枢神经肿瘤放疗乳腺癌放疗姑息放疗与转移瘤

拉帕替尼同步联合脑部放疗治疗HER2阳性乳腺癌脑转移患者:NRG Oncology-KROG/RTOG 1119 2期随机试验

Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+ Breast Cancer With Brain Metastases: NRG Oncology-KROG/RTOG 1119 Phase 2 Randomized Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-07-26

该2期随机试验纳入HER2阳性乳腺癌伴至少1个可测量未照射脑转移灶的患者,随机接受全脑放疗(37.5 Gy/3周)或立体定向放射外科(按大小给药)±同步拉帕替尼(1000 mg每日,共6周)。放疗联合拉帕替尼未改善12周颅内完全缓解率(0% vs 单纯放疗6%,单侧P=0.97)或12周客观缓解率,但4周客观缓解率在联合组更高(55% vs 42%)。

要点

  • 放疗联合拉帕替尼未改善12周颅内完全缓解率(0% vs 6%,单侧P=0.97)。
  • 4周客观缓解率联合组为55%,单纯放疗组为42%。
  • 3级和4级不良事件发生率:单纯放疗8%和0%,联合组28%和6%。

核心结论

  • 同步拉帕替尼联合全脑放疗或立体定向放射外科未改善12周颅内完全缓解率这一主要终点,也未改善12周客观缓解率。
  • 联合拉帕替尼改善了4周客观缓解率,提示同步治疗可能带来短期获益。

研究设计与样本

  • 本研究为2期随机试验,纳入HER2阳性乳腺癌伴至少1个可测量、未照射脑转移灶的患者。
  • 患者随机接受全脑放疗(37.5 Gy/3周)或立体定向放射外科(按病灶大小给药),联合或不联合同步拉帕替尼(1000 mg每日,共6周)。
  • 2012年7月至2019年9月共随机143例患者,其中116例可分析主要终点。

主要发现

  • 放疗联合拉帕替尼组12周颅内完全缓解率为0%,单纯放疗组为6%(单侧P=0.97)。
  • 4周客观缓解率联合组为55%,单纯放疗组为42%。
  • 分级预后评估较高和病灶数≤10个与较高的12周客观缓解率相关。
  • 3级不良事件发生率单纯放疗组为8%,联合组为28%;4级不良事件发生率单纯放疗组为0%,联合组为6%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lapatinib plus whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) was hypothesized to improve the 12-week intracranial complete response (CR) rate compared with either option of radiation therapy (RT) alone for patients with brain metastases (BM) from human epidermal growth factor receptor 2-positive (HER2+) breast cancer. METHODS AND MATERIALS: This study included patients with HER2+ breast cancer with ≥1 measurable, unirradiated BM. Patients were randomized to WBRT (37.5 Gy/3 wk)/SRS (size-based dosing) ± concurrent lapatinib (1000 mg daily for 6 weeks). Secondary endpoints included objective response rate (ORR), lesion-specific response, central nervous system progression-free survival, and overall survival. RESULTS: From July 2012 to September 2019, 143 patients were randomized, with 116 analyzable for the primary endpoint. RT + lapatinib did not improve 12-week CR (0% vs 6% for RT alone, 1-sided P = .97), or ORR at 12 weeks. At 4 weeks, RT + lapatinib showed higher ORR (55% vs 42%). Higher graded prognostic assessment and ≤10 lesions were associated with higher 12-week ORR. Grade 3 and 4 adverse event rates were 8% and 0% for RT and 28% and 6% for RT + lapatinib. CONCLUSIONS: The addition of 6 weeks of concomitant lapatinib to WBRT/SRS did not improve the primary endpoint of 12-week CR rate or 12-week ORR. Adding lapatinib to WBRT/SRS showed improvement of 4-week ORR, suggesting a short-term benefit from concomitant therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kim IA, Winter KA, Sperduto PW, et al. Concurrent Lapatinib With Brain Radiation Therapy in Patients With HER2+ Breast Cancer With Brain Metastases: NRG Oncology-KROG/RTOG 1119 Phase 2 Randomized Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37506981. doi:10.1016/j.ijrobp.2023.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。